| Stem Cell Research and Therapy |
1 |
1 |
| Biologic Therapy |
0 |
0.9 |
| Transplantation |
0 |
0.98 |
| Cell Transplantation |
0 |
0.97 |
| Multiple Myeloma |
0 |
0.99 |
| Transplant Program |
0 |
0.51 |
| Heart Transplantation |
0 |
0.45 |
| Cardiomyopathy |
0 |
0.37 |
| Heart Failure (HF) |
0 |
0.37 |
| Immunomodulator |
0 |
0.26 |
| Cancer |
0 |
0.21 |
| Toxicology |
0 |
0.17 |
| Blood |
0 |
0.13 |
| Monoclonal Antibody |
0 |
0.13 |
| Acute Myeloblastic Leukemia |
0 |
0.06 |
| Myelodysplastic Syndrome |
0 |
0.06 |
| Acute Leukemia |
0 |
0.05 |
| Adverse Effects |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Healthcare and Medical Technology |
0 |
0.04 |
| Heart |
0 |
0.04 |
| Leukemia |
0 |
0.04 |
| Lung |
0 |
0.04 |
| New York |
0 |
0.04 |
| Patient Safety |
0 |
0.04 |
| Proteasome Inhibitor |
0 |
0.04 |
| Quality of Life |
0 |
0.04 |